Skip to main content
Premium Trial:

Request an Annual Quote

Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

NEW YORK (GenomeWeb) — Decipher Biosciences — formerly GenomeDx Biosciences — announced today that it has signed an agreement to help Dendreon Pharmaceuticals identify patients who are likely to respond to its prostate cancer therapy Provenge (sipuleucel-T).

Provenge is a US Food and Drug Administration-approved autologous cellular immunotherapy. Under the terms of the deal, the Decipher assay will be used to assess the biological behavior of tumors from patients enrolled in a phase III study of Provenge. It will also evaluate tumor gene expression signatures that may be associated with Provenge response..

The Decipher assay is designed to provide a genomic assessment of tumor aggressiveness for individual patients and is derived from the San Diego-based company's Genomics Resource Information Database of urologic tumor genomic profiles.

Additional terms were not disclosed